NCT00307177View on ClinicalTrials.gov

Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
Influenza
Interventions
BIOLOGICAL

Trivalent inactivated influenza vaccine

Standard Trivalent inactivated influenza vaccine, licensed. Arm A receives standard dose of 15 mcg IM on day 0.

BIOLOGICAL

Trivalent Baculovirus-expressed Influenza HA vaccine

Trivalent Baculovirus-expressed influenza HA vaccine (Recombinant rHA0): Arms B, C and D receive 15 mcg, 45 mcg or 135 mcg IM dose on Day 0.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00307177 - Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma | Biotech Hunter | Biotech Hunter